Daily Anesthesiology Research Analysis
Today’s top anesthesiology papers addressed three practical perioperative questions: whether GLP-1 agonists increase aspiration risk during upper endoscopy, whether liposomal bupivacaine improves outcomes when used for QLB-LSAL after laparoscopic nephrectomy, and whether BIS-guided anesthesia benefits pediatric recovery. Evidence suggests no significant aspiration signal with GLP-1 agents, clinically meaningful opioid-sparing with liposomal bupivacaine in QLB-LSAL, and modest but consistent reco
Summary
Today’s top anesthesiology papers addressed three practical perioperative questions: whether GLP-1 agonists increase aspiration risk during upper endoscopy, whether liposomal bupivacaine improves outcomes when used for QLB-LSAL after laparoscopic nephrectomy, and whether BIS-guided anesthesia benefits pediatric recovery. Evidence suggests no significant aspiration signal with GLP-1 agents, clinically meaningful opioid-sparing with liposomal bupivacaine in QLB-LSAL, and modest but consistent recovery advantages with BIS guidance in children.
Research Themes
- Perioperative risk management for GLP-1 agonists and aspiration
- Opioid-sparing regional anesthesia with extended-release local anesthetics
- Pediatric precision anesthesia and monitoring with BIS
Selected Articles
1. Liposomal Bupivacaine for Quadratus Lumborum Block at the Lateral Supra-Arcuate Ligament in the Analgesic Effect After Laparoscopic Nephrectomy: A Single-Centre, Triple-Blind, Randomized Controlled Trial.
In a triple-blind RCT of patients undergoing laparoscopic nephrectomy, liposomal bupivacaine used for QLB-LSAL significantly reduced 48-hour morphine-equivalent consumption and improved quality of recovery without increasing adverse events. The between-group difference in opioid consumption was approximately 10–12 morphine-milligram equivalents with P<0.001.
Impact: Demonstrates clinically meaningful opioid-sparing and recovery benefits with an extended-release local anesthetic in a contemporary fascial plane block.
Clinical Implications: Supports incorporating liposomal bupivacaine for QLB-LSAL in multimodal analgesia after laparoscopic nephrectomy, with attention to cost and access considerations.
Key Findings
- Triple-blind RCT showed significantly lower 48-hour morphine-equivalent consumption with liposomal bupivacaine (between-group difference ~10–12 MME; P<0.001).
- Quality of recovery exceeded the minimal clinically important difference in the liposomal bupivacaine group.
- No significant difference in adverse events between groups.
Methodological Strengths
- Triple-blind, randomized controlled design with prespecified primary endpoint.
- Clinically meaningful outcomes (opioid consumption and validated recovery scores).
Limitations
- Single-center study; generalizability may be limited.
- Not powered to detect rare adverse events or long-term outcomes (e.g., chronic postsurgical pain).
Future Directions: Multicenter, cost-effectiveness trials comparing liposomal vs. standard bupivacaine across procedures; pharmacokinetic profiling within fascial plane blocks; assessment of chronic pain and functional recovery.
PURPOSE: Quadratus lumborum block at the lateral supra-arcuate ligament (QLB-LSAL) has demonstrated efficacy in postoperative pain management for laparoscopic nephrectomy patients. Liposomal bupivacaine, a novel sustained-release local anesthetic, provides analgesia lasting up to 72 hours. However, its analgesic effect in QLB-LSAL remains undetermined. This randomized controlled trial aimed to compare the postoperative analgesic efficacy of liposomal bupivacaine versus bupivacaine hydrochloride in patients receiving QLB-LSAL after laparoscopic nephrectomy. PATIENTS AND METHODS: A total of 116 patients were scheduled to undergo elective laparoscopic nephrectomy under general anesthesia. Patients were randomly assigned to two groups in a 1:1 ratio. The liposomal bupivacaine group (n = 53) received a mixture of 10 mL of liposomal bupivacaine (133mg) and 10 mL of normal saline, totaling 20 mL, while the bupivacaine hydrochloride group (n = 53) received 20 mL of 0.375% bupivacaine hydrochloride. Post-surgical patient-controlled sufentanil analgesia was provided. The primary outcome was total morphine equivalent consumption within the first 48 hours postoperatively. RESULTS: The total consumption of morphine equivalents within 48 hours postoperatively was significantly lower in the liposomal bupivacaine group than in the bupivacaine hydrochloride group (mean ± SD: 31.8 ± 2.3 vs 20.7 ± 2.8, 95% Confidence Intervals: 10.1 to 12.1, P < 0.001). The liposomal bupivacaine group demonstrated superior postoperative recovery quality (P < 0.05), exceeding the minimal clinically important difference, whereas no significant difference in the incidence of adverse events (P > 0.05) was observed between the two groups. CONCLUSION: The findings demonstrated that administration of liposomal bupivacaine in QLB-LASL significantly reduced postoperative opioid consumption while concurrently improving recovery quality in patients undergoing laparoscopic nephrectomy.
2. Bispectral index-guided anesthesia in children: A systematic review and meta-analysis.
Across 10 pediatric RCTs (n=1028), BIS-guided anesthesia modestly shortened airway removal and recovery times, reduced PACU stay, and lowered end-tidal sevoflurane concentration, without affecting emergence delirium scores. Findings support BIS as a tool to limit volatile exposure and improve recovery metrics in children.
Impact: Synthesizes pediatric RCT evidence clarifying benefits of BIS guidance on recovery metrics and anesthetic exposure, informing monitoring strategies.
Clinical Implications: Consider BIS monitoring in pediatric general anesthesia to reduce volatile anesthetic exposure and modestly expedite recovery, while recognizing effects on emergence delirium may be limited.
Key Findings
- Airway device removal time reduced by 1.32 minutes (MD -1.32; 95% CI -2.26 to -0.37).
- Recovery time reduced by 2.67 minutes and PACU stay reduced by 5.51 minutes versus standard care.
- End-tidal sevoflurane concentration decreased by 0.49%; no difference in PAED scores at 10 or 30 minutes.
Methodological Strengths
- Systematic review and meta-analysis of RCTs with PROSPERO registration.
- Heterogeneity assessed (I²), multiple clinically relevant recovery outcomes synthesized.
Limitations
- Heterogeneity across surgeries, ages, and anesthetic techniques; modest absolute time differences.
- No demonstrated effect on emergence delirium; anesthetic consumption endpoints varied.
Future Directions: Prospective trials to assess impact on postoperative delirium, cognitive outcomes, and cost-effectiveness; define age-specific BIS targets.
INTRODUCTION: The bispectral index (BIS) parameter is used to guide the titration of general anesthesia; however, many studies have shown conflicting results regarding its benefits in children. We aimed to perform a systematic review and meta-analysis to determine whether BIS is advantageous for pediatric patients undergoing general anesthesia. METHODS: PubMed, Embase, and Cochrane Library were systematically searched for randomized controlled trials (RCTs) comparing BIS-guided anesthesia vs. general anesthesia guided only by clinical parameters in children undergoing surgeries. We computed mean difference (MD) for continuous outcomes and risk ratio (RR) for binary outcomes, with 95% confidence intervals (CIs). Heterogeneity was assessed using I² statistics. Statistical analyses were performed using R Software, version 4.2.3. RESULTS: We included 10 RCTs, comprising 1028 participants, of whom 536 (52%) underwent BIS-guided general anesthesia. Compared with general anesthesia guided solely by clinical parameters, BIS was associated with a lower time for airway device removal (MD -1.32 min; 95% CI -2.26 to -0.37; p < 0.01), recovery time (MD -2.67 min ; 95% CI -3.70 to -1.65; p < 0.01), PACU stay duration (MD -5.51 min; 95% CI -10.64 to -0.38; p = 0.04), and ET sevoflurane concentration (MD -0.49%; 95% CI -0.67 to -0.32; p < 0.01). The BIS guided group also showed a significantly longer time with an adequate BIS compared with the standard care group (MD 22.49%; 95% CI 17.80-27.18; p < 0.01). There were no differences between groups in anesthetic consumption, mean BIS during anesthesia, Pediatric Anesthesia Emergence Delirium (PAED) score at 10 min, and at 30 min. CONCLUSIONS: In children, BIS monitoring during general anesthesia limited the exposure to volatile anesthetics and is associated with better recovery outcomes. REGISTRATION: PROSPERO database under protocol number CRD42024607202 (https://www.crd.york.ac.uk/PROSPERO/view/CRD42024607202).
3. GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.
This PROSPERO-registered meta-analysis of 12 studies (n=210,216) found no significant association between GLP-1 agonist use and pulmonary aspiration during elective upper endoscopy (OR 1.23; 95% CI 0.58–2.60; P=0.59). Rare aspiration occurred even after drug cessation >6 days and standard fasting, underscoring management gaps and the need for standardized pathways.
Impact: Addresses a high-visibility perioperative controversy with large-scale evidence, informing evolving guidance on GLP-1 agent management before procedures.
Clinical Implications: Routine discontinuation solely to mitigate aspiration risk during elective upper endoscopy may be unnecessary; instead, pursue patient-specific risk stratification, consider gastric ultrasound in high-risk cases, and standardize fasting protocols while awaiting prospective data.
Key Findings
- Across 12 studies (n=210,216), aspiration risk with GLP-1 agonists was not significantly increased (OR 1.23; 95% CI 0.58–2.60; P=0.59).
- Observed aspiration incidence was low: 0.16% in GLP-1 users vs 0.12% in controls.
- Three aspiration events occurred despite stopping GLP-1 >6 days and fasting >8 hours, highlighting protocol variability and residual risk.
Methodological Strengths
- Registered protocol (PROSPERO CRD42024595241) and PRISMA-concordant synthesis.
- Very large pooled sample across multiple settings.
Limitations
- Predominantly retrospective observational data with potential residual confounding.
- Heterogeneity in fasting protocols, procedural sedation/anesthesia, and timing of GLP-1 discontinuation; few or no RCTs.
Future Directions: Prospective trials with standardized fasting, peri-procedural algorithms, and point-of-care gastric ultrasound to refine risk stratification and guidance for GLP-1 users.
INTRODUCTION: Glucagon-like Peptide-1 (GLP-1) agonists cause delayed gastric emptying by acting on vagal afferent nerves. Retained gastric contents (RGC) increase the risk of pulmonary aspiration, particularly under anesthesia in endoscopic procedures. This systematic review and meta-analysis aim to summarize the current evidence on pulmonary aspiration in patients receiving GLP-1 agonists undergoing endoscopy. METHODS: A systematic review was conducted using Cochrane, Embase, and PubMed from inception to May 2024, including studies and case reports examining GLP-1 agonists and pulmonary aspiration. Data on study characteristics, patient demographics, and GLP-1 agonist use were collected. A pooled analysis of retrospective studies was performed using RevMan version 5.4.1. The study protocol was registered in the PROSPERO database (ID CRD42024595241). RESULTS: A total of five case reports involving six patients and twelve studies including 210,216 patients were identified. Pulmonary aspiration occurred in 143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group. Notably, three patients experienced aspiration despite stopping GLP-1 agonists more than six days prior and fasting for over eight hours. The meta-analysis showed an odds ratio of 1.23 (P = 0.59; 95% CI, 0.58 to 2.60) for pulmonary aspiration associated with GLP-1 agonist use, which was not statistically significant. DISCUSSION: This analysis did not find a statistically significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopic procedures. While the findings align with some existing studies suggesting minimal increased risk, the presence of aspiration cases despite prolonged fasting highlights potential gaps in current peri-procedural management. Limitations include reliance on retrospective data and case reports, as well as variability in fasting protocols. CONCLUSION: The study found no significant association between GLP-1 agonist use and pulmonary aspiration risk during endoscopy. Further research is warranted to develop evidence-based fasting guidelines and optimize peri-procedural management for patients on GLP-1 agonists.